Skip to search formSkip to main contentSkip to account menu

PCR Regimen

Known as: Pentostatin-Cyclophosphamide-Rituximab Regimen 
A regimen consisting of pentostatin, cyclophosphamide and rituximab used to treat relapsed or refractory mantle cell lymphoma.
National Institutes of Health

Related topics

Related topics

5 relations
CyclophosphamidePentostatinRefractory Mantle Cell Lymphomarecurrent mantle cell lymphoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia.
6568 Background: Combination therapy with purine analogs, alkylators, and/or monoclonal antibodies represents a promising new… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)